ibio inc (IBIO) Key Developments
iBio, Inc. Reports the Initiation of Phase 1 Human Safety and Immunogenicity Clinical Study of Transmission-Blocking Malaria Vaccine Candidate
Feb 10 14
iBio, Inc. reported the initiation of a Phase 1 human safety and immunogenicity clinical study of a transmission-blocking malaria vaccine candidate. The vaccine candidate was produced on the company's proprietary iBioLaunch(TM) platform by the Fraunhofer USA Center for Molecular Biotechnology. Fraunhofer USA Center for Molecular Biotechnology (FhCMB) announced that clearance was obtained from the U.S. Food and Drug Administration (FDA) for an investigational new drug (IND), Fraunhofer's plant-derived malaria transmission-blocking vaccine (TBV), which targets the Pfs25 antigen, to proceed into the clinic in a Phase 1 safety and immunogenicity study.
iBio, Inc. Adds Biotherapeutic Product for Treatment of Fibrosis to Its Proprietary Product Pipeline
Jan 30 14
iBio, Inc. has added a proprietary biotherapeutic product for the treatment of idiopathic pulmonary fibrosis (IPF) and systemic sclerosis to its product pipeline. iBio obtained license to patents and related intellectual property for this novel therapy, and then entered a collaboration agreement with the Medical University of South Carolina (MUSC), the inventor and now the Kitty Trask Holt and SmartState SC Centers of Economic Excellence Endowed Professor at MUSC, that will enable iBio to advance the development of a potentially breakthrough biotherapeutic product against these otherwise unstoppable diseases. Effective treatment of IPF, systemic sclerosis and localized scleroderma, represents an unmet medical need. Although some limited results have been claimed for existing therapies, there are currently no effective therapies for stopping or reversing fibrosis.
iBio and Caliber Designate New Fusion Protein as Target Product Under License and Collaboration Agreement
Jan 15 14
iBio, Inc. announced that the company and Caliber Biotherapeutics have designated a proprietary fusion protein for cancer treatment as the first product target for advancement on the iBioLaunch platform under the License and Collaboration Agreement between the company and Caliber dated February 14, 2013. Under the terms of the agreement between iBio and Caliber, iBio will receive license and milestone fees for development of product targets. Caliber is responsible for funding clinical development and commercialization of such collaboration products, and iBio is entitled to receive royalties on such product sales and other revenues.
iBio, Inc. Elects Glenn Chang and Philip K. Russell as Class II Directors; Amends Certificate of Incorporation
Dec 18 13
At the iBio, Inc.'s 2013 Annual Meeting of Stockholders elected Glenn Chang and Philip K. Russell, M.D. to serve as Class II directors of the company for a three-year term expiring in 2016.
The company stockholders also approve the an amendment to the certificate of incorporation increasing the authorized number of shares of common stock from 100 million to 175 million.
iBio, Inc. Announces Executive Changes
Dec 5 13
iBio, Inc. appointed Mark Giannone, age 57, to serve as Chief Financial Officer of the company, replacing Scott Kain, whose departure was effective November 30, 2013. His prior experience included employment as a senior accountant at Kenneth Leventhal & Co. and as a tax manager at BDO Seidman, a lecturer in various continuing education programs for the New York State Society of Certified Public Accountants and New York University.